Artimplant employs new Marketing Manager

Artimplant employs new Marketing Manager

Västra Frölunda, Sweden, September 3, 2007
The biomaterials company Artimplant, employs Kauko Haapasaari as new Marketing
Manager. Mr Haapasaari will assume his new responsibility on October 1st.

Mr Haapasaari is presently director of business development at Raisio
Diagnostics. He has previously held marketing and sales positions at Conpharm,
SP-Maskiner, Swedish Trade Council, Instrument Lambda and KabiVitrum.

Kauko Haapasaari holds a B.Sc in Chemical and Administrative Sciences and brings
to Artimplant more than 24 years of experience in the life science business."I have the highest expectations when bringing my knowledge and experience to
Artimplant. I believe that my successful sales and marketing career within the
life science industry will be an excellent platform for my tasks at Artimplant.
I look forward to working with the healthcare providers to make them embrace the
biomaterial Artelon® to improve the quality of life among their patients," says
Kauko Haapasaari.

Hans Rosén, CEO of Artimplant comments: "It's with great pleasure we welcome
Kauko, with his solid background, to the Artimplant team. We will benefit from
his intimate experience of international marketing and sales within the life
science industry. Mr Haapasaari will be responsible for the marketing and sales
of Artimplant's products.”

For additional information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Web site: www.artimplant.com

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.


Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.